Two Treatments For IPF Edge Closer To Market, Will Come Down To Subtle Differences
This article was originally published in The Pink Sheet Daily
InterMune’s pirfenidone and Boehringer Ingelheim’s nintedanib are neck-and-neck in the race to be the first drug interventions in the U.S. for the fatal lung disease. Phase III data from both drugs were presented at the American Thoracic Society meeting and published in the NEJM May 18.
You may also be interested in...
Roche’s Esbriet and Boehringer’s Ofev become the first drugs approved by FDA for idiopathic pulmonary fibrosis; Velcade approved for first-line mantle cell lymphoma; Lymphoseek cleared for solid tumors; Acura mulls next steps after losing appeal on abuse-deterrent claim for Vycavert.
FDA approved the first two drugs for the fatal lung disease idiopathic pulmonary fibrosis: Roche’s Esbriet and Boehringer Ingelheim’s Ofev. The simultaneous approvals set the stage for a commercial showdown.
Phase III trial of idiopathic pulmonary fibrosis drug puts company in strong position for FDA approval of first treatment for orphan disease and strong reimbursement in U.S. and abroad.